Novartis AG (NYSE:NVS) Shares Purchased by Tucker Asset Management LLC

Tucker Asset Management LLC boosted its position in Novartis AG (NYSE:NVS - Free Report) by 11,352.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,405 shares of the company's stock after purchasing an additional 2,384 shares during the period. Tucker Asset Management LLC's holdings in Novartis were worth $234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of NVS. Bryn Mawr Capital Management LLC raised its stake in shares of Novartis by 0.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company's stock valued at $1,254,000 after acquiring an additional 100 shares in the last quarter. Rothschild Investment LLC raised its position in Novartis by 0.6% during the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company's stock valued at $1,623,000 after purchasing an additional 101 shares in the last quarter. Meridian Wealth Management LLC raised its position in Novartis by 2.6% during the 4th quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company's stock valued at $405,000 after purchasing an additional 106 shares in the last quarter. Angeles Wealth Management LLC lifted its holdings in shares of Novartis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company's stock worth $316,000 after buying an additional 110 shares during the period. Finally, Heritage Family Offices LLP grew its position in shares of Novartis by 1.9% during the 4th quarter. Heritage Family Offices LLP now owns 6,107 shares of the company's stock worth $594,000 after buying an additional 112 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Morgan Stanley began coverage on shares of Novartis in a research note on Wednesday, February 12th. They set an "underweight" rating on the stock. Barclays reaffirmed an "underweight" rating on shares of Novartis in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft raised Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. HSBC downgraded Novartis from a "hold" rating to a "reduce" rating in a research report on Wednesday, December 4th. Finally, UBS Group reissued a "neutral" rating on shares of Novartis in a research report on Thursday, February 13th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $123.38.

Novartis Stock Performance

NYSE NVS traded up $0.57 on Wednesday, hitting $110.18. 1,316,382 shares of the company's stock traded hands, compared to its average volume of 1,501,202. The firm's 50-day moving average price is $108.40 and its two-hundred day moving average price is $107.06. The firm has a market capitalization of $225.21 billion, a PE ratio of 18.74, a P/E/G ratio of 1.70 and a beta of 0.53. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.

Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. As a group, analysts expect that Novartis AG will post 8.45 EPS for the current year.

Novartis Dividend Announcement

The company also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were issued a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is 42.69%.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.